Chronic Myelocytic Leukemia Clinical Trial
Official title:
The Catholic University of Korea Cancer Research Institute
This study is designed to confirm the efficacy of dasatinib 100mg once daily in producing a complete molecular response and to prove a possibility of "Operational Cure" in CMR patients.
This study also examines kinetics of complete molecular responses using new highly sensitive PCR based technology, digital PCR, which is reported to have a sensitivity down to 6 log reduction. ;
Observational Model: Cohort
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00854646 -
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
| Recruiting |
NCT04150471 -
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
|
||
| Recruiting |
NCT04256317 -
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
|
Phase 2/Phase 3 | |
| Terminated |
NCT01300611 -
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
|
Phase 1 | |
| Terminated |
NCT01621477 -
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
|
Phase 2 |